Qureight

By unlocking the power of clinical and imaging data to advance the understanding of complex disease progression, Qureight’s technology plays a pivotal role in efforts to improve patient outcomes and extend lives.

Qureight announced a Series A raise of $8.5m in Q2 2024 and is poised to target a range of disease areas in markets worth billions, including an expansion into new disease areas such as lung cancer.

The company’s collaborators and research partners include some of the most renowned healthcare institutes and pharmaceutical companies globally (AstraZeneca, Vicore Pharma, and several NHS Trusts), and investors include Cambridge Angels, Meltwind, CMS Ventures, Playfair, and Ascension.

Career opportunities at Qureight